PHK
ATRA icon

Point72 Hong Kong’s Atara Biotherapeutics ATRA Stock Holding History

Point72 Hong Kong’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-257
Closed -$24K – 186
2022
Q3 		$24K Buy
+257
New +$28.9K ﹤0.01% 1586
2022
Q2 		– Sell
-289
Closed -$67K – 1902
2022
Q1 		$67K Buy
289
+224
+345% +$71.3K ﹤0.01% 1262
2021
Q4 		$26K Sell
65
-249
-79% -$105K ﹤0.01% 1497
2021
Q3 		$140K Buy
314
+289
+1,156% +$104K ﹤0.01% 1261
2021
Q2 		$10K Sell
25
-44
-64% -$15.7K ﹤0.01% 1738
2021
Q1 		$25K Sell
69
-55
-44% -$24.3K ﹤0.01% 1425
2020
Q4 		$61K Buy
+124
New +$57.2K ﹤0.01% 1171
2020
Q3 		– Sell
-213
Closed -$78K – 1183
2020
Q2 		$78K Buy
+213
New +$53.8K 0.01% 676
2019
Q3 		– Sell
-29
Closed -$15K – 998
2019
Q2 		$15K Buy
+29
New +$20.5K ﹤0.01% 816

Other funds holding ATRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Point72 Hong Kong's ATRA Position: Q4 2022 in Review

Point72 Hong Kong sold out of Atara Biotherapeutics (ATRA) in Q4 2022, closing a stake of 257 shares — an estimated $24K sold.

Point72 Hong Kong first reported a position in ATRA in Q2 2019 and held it in 9 quarters. The position peaked at $140K in Q3 2021. 138 funds tracked by Wall St. Rank hold ATRA as of Q4 2022.

  • Point72 Hong Kong reported no remaining Atara Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 257 Atara Biotherapeutics shares in Q4 2022, an estimated $24K.
  • Point72 Hong Kong first reported a position in Atara Biotherapeutics in Q2 2019 and held it in 9 quarters.
  • Point72 Hong Kong's Atara Biotherapeutics position peaked at $140K in Q3 2021.
  • 138 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.